Arthralgia is a common and debilitating adverse effect experienced by patients with breast cancer who are being treated with aromatase inhibitors, often resulting in poor adherence. (ascopost.com)
When addressing hormone therapy, whether aromatase inhibitors (AIs) or selective modulators of estrogen receptors (SMREs), different adverse effects are observed ( Early Breast Cancer Trialists' Collaborative Group, 2015 ). (e-jer.org)
Inhibitor1
Prolia ® is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. (proliahcp.com)
Breast cancer1
The aim of this study was to evaluate the influence of adherence to mat Pilates training on lower and upper body strength and flexibility in breast cancer survivors. (e-jer.org)
High2
For this secondary investigation only the intervention group was analyzed, divided into low and high training adherence. (e-jer.org)
0.05) between high and low adherence for physical activity level before and after the intervention. (e-jer.org)
Treatment choices with these agents include the use of an aromatase inhibitor as an upfront strategy for 5 years, as a sequential approach after 2-3 years of tamoxifen, or as an extended use after the classical 5 years of tamoxifen. (nih.gov)
Moreover, according to the optimal duration of therapy, presently it is not known whether aromatase inhibitor therapy, as tamoxifen, should be limited to 5 years. (nih.gov)
For patients with ER+ breast cancer who have been initiated on adjuvant endocrine therapy (e.g. either single agent or sequential agent - tamoxifen and/or an aromatase inhibitor), encourage endocrine therapy adherence and assess for side effects and complications. (breastcancersurvivorship.net)
Postmenopausal women1
There is strong evidence to support the use of adjuvant endocrine therapy with aromatase inhibition for postmenopausal women for 5 years or more, depending on recurrence risk and tolerance to the medication. (medscape.com)
Endocrine1
28. Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity. (nih.gov)
Inhibitor therapy1
Prolia ® is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. (proliahcp.com)
The overall effectiveness of this therapy depends on adherence, which remains a stubborn problem for patients and clinicians. (medscape.com)
Incidence1
The incidence of aromatase inhibitor induced musculo skeleton syndrome is higher with women with the last menstrual period within five years. (standardofcare.com)